Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

Thromboembolism Clinical Trials

A listing of Thromboembolism medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (16) clinical trials

AMPLATZER LAA Occluder Post Approval Study (PAS)

The AMPLATZER LAA Occluder device will be clinically evaluated through this post approval study. This is a non-randomized multicenter study on patients who have undergone a procedure to implant an AMPLATZER LAA Occluder or will undergo an implant of an AMPLATZER LAA Occluder.

Phase N/A

Venous Thrombosis Biomarkers in Sickle Cell Disease and Sickle Cell Trait

Venous thromboembolism (VTE) the third most frequent cause of vascular mortality after myocardial infarction and stroke, occurs more frequently among Americans of African descent compared with other ethnic minorities in the US. VTEs are provoked by diverse risk factors but can be unprovoked in individuals with a hypercoagulable state, in …

Phase N/A

Cardiovascular Complications and COVID-19 (CovCardioVasc)

Patients with COVID-19 in the Intensive Care Unit (ICU) or hospitalized with severe form have a poor prognosis (almost 30% rate of death). They present often a high cardiovascular risk profile (almost 30% of hypertension and 19% of diabetes). Troponin has been described to be elevated in a high proportion …

Phase N/A

Coagulation System In STereotactic Radiotherapy Of NSCLC

In this study, the patients will have blood samples drawn three times (prior to start of stereotactic body radiation therapy, immediately after stereotactic body radiation therapy completion, four to six weeks after completing stereotactic body radiation therapy). The blood sample at the completion of stereotactic body radiation therapy is an …

Phase N/A

Filter Initial & Long Term Evaluation After Placement and Retrieval Registry

Patient clinical data will be used in a clinical registry. Before a patient is to undergo their initial procedure for filter placement/retrieval, we will approach them for consent to participate in the study. If patients consent, we will follow clinical data from the procedure, and perform prospective follow-up over time …

Phase N/A

Anticoagulation Length of ThErapy and Risk of New Adverse evenTs In Venous thromboEmbolism Study

Venous thromboembolism (VTE) is a leading cause of cardiovascular death and continues to be a major public health issue in the United States. The cornerstone of current VTE treatment is anticoagulation, typically given for 3 months during the acute phase of thrombosis. Afterwards, extended-duration anticoagulation can be considered for selected …

Phase N/A

START-Register: Survey on Anticoagulated Patients Register

Participants can include patients with 18 years or more who satisfy the following preset criteria Participants should included patients consecutively to avoid selection bias; criteria to avoid selection bias are proposed to Participants, which should decide the one they want to adopt. Patients should have been receiving anticoagulation therapy for …

Phase N/A

Biomarkers of Thrombosis as Predictors of Venous Thromboembolism Risk in Cancer Patients

The main aims will be the following: Evaluate the utility of the combination of thrombosis biomarkers (D-dimers and thrombin generation potential) with the Khorana score in order to stratify VTE risk in ambulatory cancer patients; Determine the potential of this new score in the stratification of cancer patients into high- …

Phase N/A

RIVET-Case Control Study

This population-based case-control study will be conducted in Germany and Austria. It is intended to recruit the VTE cases from the primary care sector (i.e. community based) before referral to specialized centers/hospitals, from hospitals (emergency department or internal medicine ward) or when the cases are referred back to ambulatory care …

Phase N/A

Biomarkers of Acute Stroke in Clinic

Acute ischemic stroke (AIS) is a leading cause of adult mortality and morbidity in the United States, affecting over 800,000 individuals, annually, leaving many with permanent disability. Emergent evaluation, prompt acute treatment, and identification of stroke etiology for secondary prevention are key to decreasing the morbidity and mortality associated with …

Phase N/A